Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Michelle Dimauro

Nurse Practitioner New Milford, CT Nurse Practitioner

NPI 1760935373 CMS profile 10844369

131 Kent Rd, Ste 2, New Milford, CT 06776

Open in the dashboard

General payments

$5,805

261 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Dimauro of New Milford, CT is reported in the CMS Open Payments database as having received $5,805 across 261 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,632 88
2024 General $1,842 68
2023 General $1,833 89
2022 General $497 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Dimauro
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Michelle Dimauro were reported at $1,632. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Michelle Dimauro Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $497 $152 $48–$470 $149
2023 $1,833 $166 $54–$529 $160
2024 $1,842 $173 $55–$556 $164
2025 $1,632 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $1,488 43 payments
  2. GlaxoSmithKline, LLC. $1,364 94 payments
  3. Genzyme Corporation $780 24 payments
  4. Amgen Inc. $540 27 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $371 11 payments
  6. Regeneron Healthcare Solutions, Inc. $352 17 payments
  7. Novartis Pharmaceuticals Corporation $141 7 payments
  8. CSL Behring $136 6 payments
  9. Pfizer Inc. $105 5 payments
  10. kaleo, Inc. $82 4 payments
  11. Other $445 23 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $5,768 259 payments
  2. Education $37 2 payments
Products named General payments · program years 2022–2025
  1. NUCALA $1,255 86 payments
  2. DUPIXENT Immunology $1,031 34 payments
  3. TEZSPIRE Respiratory $893 23 payments
  4. TEZSPIRE Inflammation $540 27 payments
  5. BREZTRI $446 11 payments
  6. AIRSUPRA $361 8 payments
  7. DUPIXENT Inflammation And Immunology $214 10 payments
  8. DUPIXENT Immunology And Inflammation $138 7 payments
  9. SPIRIVA RESPIMAT $137 9 payments
  10. EOHILIA $136 6 payments
  11. Other $1,346 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

192

Median for Nurse Practitioner: 389

Drug cost

$36,983

Median for Nurse Practitioner: $21,885

Branded share of claims

46.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 21 $17,344
Spiriva Respimat Tiotropium Bromide Brand 17 $8,837
Epinephrine Generic 31 $5,225
Symbicort Budesonide/Formoterol Fumarate Brand 12 $2,692
Asmanex Hfa Mometasone Furoate Brand 14 $1,622
Albuterol Sulfate Hfa Albuterol Sulfate Brand 25 $429
Montelukast Sodium Generic 39 $367
Fluticasone Propionate Generic 22 $252
Famotidine Generic 11 $215

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$43,542

Medicare's payments for the services billed

Medicare patients

80

Average age 71

Services billed

2,377

50 women, 30 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 58%
Arthritis 43%
Depression 28%
Osteoporosis 18%
COPD 16%
Cancer 15%
Heart failure 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $393
  • Regeneron Healthcare Solutions, Inc. $128
$520 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $173
  • Amgen Inc. $135
$308 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $215
$215 — —
NUCALA
  • GlaxoSmithKline, LLC. $160
$160 — —
EOHILIA
  • Takeda Pharmaceuticals U.S.A., Inc. $109
$109 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

261 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record